EPG Online Twitter 
EPG Online Blog 
Disease Knowledge Drug Updates
- Bedranol 80mg SR Capsules
- Bedranol 160mg SR Capsules
- Betim 10mg Tablets
- Carbo-Dome Cream
- Bisoprolol 2.5mg/5mg/10mg film coated tablet
- Eprex 2000, 4000 and 10000 IU/ml solution for injection in pre-filled syringe
- Epanutin 300mg hard capsules
- Epanutin capsules 25, 50 and 100mg
- FemSeven Conti
- Rivotril 0.5 mg and 2 mgTablets
- RELPAX 20mg and 40mg Film-Coated Tablets
- Rivotril Ampoules
- Phenergan Injection
- Witch Doctor ® 81.5%w/w Gel
- Levetiracetam Actavis 1,000 mg film-coated tablets
- Lidocaine Hydrochloride Injection BP 1% w/v plastic ampoules
- Levetiracetam Actavis 750 mg film-coated tablets
- Levetiracetam Actavis 500 mg film-coated tablets
- Levetiracetam Actavis 250 mg film-coated tablets
- Lidocaine Hydrochloride Injection BP 2.0% w/v
- Omeprazole 20mg Capsules
- Panadol Extra Advance 500 mg/65 mg Tablets
- Omeprazole 10mg Capsules
- Calcipotriol Scalp Solution
- Bupivacaine Hydrochloride Injection BP 0.5% w/v.
- Allopurinol Tablets BP 300mg
- Allopurinol Tablets BP 100mg
- Anadin Ultra Double Strength 400mg Capsules/Anadin LiquiFast 400mg Capsules
- Meropenem 1 g Powder for Solution for Injection or Infusion
- Lescol (fluvastatin* sodium) 20 mg and 40 mg capsules
- Vesicare 5mg & 10mg film-coated tablets
- VALTREX Tablets 250mg
- Water for Injections
- Zomig 5mg Nasal Spray
- Caverject Dual Chamber 10 micrograms & Caverject Dual Chamber 20 micrograms
- Natecal D3 Chewable Tablets
- NovoRapid 100 U/ml in a vial, NovoRapid Penfill 100 U/ml, NovoRapid FlexPen 100 U/ml, NovoRapid FlexTouch 100 U/ml
- Orfadin 2 mg hard capsules
- Orfadin 10 mg hard capsules
- Tizanidine 2mg Tablets
Multiple Sclerosis
Please note - The EPG Multiple Sclerosis Expert Centre is for Doctors and other Healthcare Professionals. Enter the Multiple Sclerosis Expert Centre.
The hallmark of multiple sclerosis (MS) as revealed by magnetic resonance imaging (MRI) is the white matter plaque, which represents an area of demyelination and axonal loss.
MS can produce lesions throughout the central nervous system (CNS), but certain sites appear to be especially vulnerable, such as the optic nerve, brain stem, spinal cord and periventricular regions. Involvement is often bilateral and symmetrical. Lesions are broadly divided into two types: acute and chronic.
Acute lesions are inflammatory in nature and exhibit infiltration by T-lymphocytes, B-lymphocytes and macrophages, which may be filled with myelin debris from the breakdown of myelin sheaths. Proliferation of astrocytes is also usually evident, accompanied by oligodendrocyte loss.
Enter the Multiple Sclerosis Expert Centre
What’s in the Multiple Sclerosis Expert Centre?
- Extavia
... determined to be at high risk of developing clinically definite multiple sclerosis. • Patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years. • Patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses ... - Betaferon
... determined to be at high risk of developing clinically definite multiple sclerosis. • patients with relapsing remitting multiple sclerosis and two or more relapses within the last two years. • patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses ... - Rebif Solution for Injection in Pre-filled Pens
Rebif is indicated for the treatment of relapsing multiple sclerosis. In clinical trials, this was characterised by two or more acute exacerbations in the previous two years. Efficacy has not been demonstrated in patients with secondary progressive multiple sclerosis without ongoing relapse activity ... - Rebif 8.8 mg injection
Rebif is indicated for the treatment of relapsing multiple sclerosis. In clinical trials, this was characterised by two or more acute exacerbations in the previous two years. Efficacy has not been demonstrated in patients with secondary progressive multiple sclerosis without ongoing relapse activity - Rebif 44mg injection
... is indicated for the treatment of relapsing multiple sclerosis. In clinical trials, this was characterised by two or more acute exacerbations in the previous two years. Efficacy has not been demonstrated in patients with secondary progressive multiple sclerosis without ongoing relapsing activity - TYSABRI 300 mg concentrate for solution for infusion
TYSABRI is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following patient groups: • Adult patients aged 18 years and over with high disease activity despite treatment with a beta-interferon. These patients may be defined as those ...
